



POSTER PRESENTATION

Open Access

# The effect of Rituximab treatment on T cells

C Diaz-Torné<sup>1</sup>, M A Ortiz<sup>2\*</sup>, C Zamora<sup>2</sup>, H Corominas<sup>3</sup>, E Perez-Ranz<sup>4</sup>, A M Laiz<sup>1</sup>, J Llobet<sup>1</sup>, C Geli<sup>1</sup>, C Juarez<sup>4</sup>, C Diaz<sup>1</sup>, S Vidal<sup>2</sup>

From 5th European Workshop on Immune-Mediated Inflammatory Diseases  
Sitges-Barcelona, Spain. 1-3 December 2010

## Introduction

Rituximab is a therapeutic anti-CD20 antibody used for in vivo depletion of B cells.

However, the mechanisms of action are not fully understood because clinical responses do not always correlate with the extent and duration of B cell depletion.

## Aim

This study was conducted to examine the effect of B cell depletion on peripheral T cells from rheumatoid arthritis patients.

## Methods

RA patients received rituximab (1000 mg). Peripheral blood samples were collected at baseline and at 30, 90 and 180 days postinfusion. The phenotype of T cell subsets of peripheral blood from RA patients were examined by cytometry and cytokine production was determined by ELISA.

## Results

According to our previous results, peripheral B cell depletion was fully effective by 30 days. No changes in the percentage of CD3+, CD4+, CD8+ and NK cells were found. There was a comparative progressive diminution of CD8+CD45RO+ cells with recovery starting at 180 days. DAS28 significantly correlated with CD8+CD45RO+ cells. Since CD8+CD45RO+ diminution was coincident with the clinical response measured as DAS28, we investigated whether IL-15 could be responsible for this population changes in rheumatoid arthritis patients. As expected there was significant levels of IL-15 in the serum RA patients (110 ± 31 pg/ml) compared to healthy donors (< 10 pg/ml). Rituximab treatment decreased IL-15 levels in serum from rheumatoid arthritis patients. Although, no significant correlation was observed between IL-15 in the

serum and CD8+CD45RO+ cells, levels of IL-15 trans-presented on the surface of neutrophils from RA patients significantly correlated with CD8+CD45RO+ (p<0.01) cells and CD8+CD45RO+/RA+ ratio (p<0.001).

## Conclusion

This study demonstrates that rituximab treatment is able to reduce IL-15 levels. This reduction could be responsible for the CD45RO+ changes during the follow-up.

## Author details

<sup>1</sup>Servei Reumatologia, Hospital S. Creu i S. Pau, Barcelona, Spain. <sup>2</sup>Dep. Immunologia, Institut Rec. Hospital S. Creu i S. Pau, Barcelona, Spain. <sup>3</sup>Servei Reumatologia, Hospital Dos de Maig, Barcelona, Spain. <sup>4</sup>Dep. Immunologia, Hospital S. Creu i S. Pau, Barcelona, Spain.

Published: 25 November 2010

doi:10.1186/1479-5876-8-S1-P66

Cite this article as: Diaz-Torné *et al.*: The effect of Rituximab treatment on T cells. *Journal of Translational Medicine* 2010 **8**(Suppl 1):P66.

Submit your next manuscript to BioMed Central  
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit



<sup>2</sup>Dep. Immunologia, Institut Rec. Hospital S. Creu i S. Pau, Barcelona, Spain  
Full list of author information is available at the end of the article